BRIEF-Audentes Therapeutics announces FDA clearance of investigational new drug application for AT132 to treat x-linked myotubular myopathy
April 3 Audentes Therapeutics Inc
* Audentes Therapeutics announces FDA clearance of investigational new drug application for AT132 to treat x-linked myotubular myopathy
* Audentes Therapeutics Inc - preliminary data from Aspiro is expected to be available in Q4 of 2017 Source text for Eikon: Further company coverage: